ASCO Annual Meeting: Prostate Cancer

Videos

Results of phase 3 CONDOR study could have a far-reaching impact on patients with prostate cancer.

Michael J. Morris, MD, on Future Directions of PSMA Imaging in Prostate Cancer 

The University of Southern California expert discusses next steps for the trial and how the recent results could impact the future of care for patients with prostate cancer.

Amir Goldkorn, MD Talks Next Steps for SWOG 1216 Trial

Results showed that once daily relugolix established superiority over leuprolide and reduced the incidence of major cardiovascular events.

Neal D. Shore, MD, FACS, Talks Findings From the Phase 3 HERO Trial

Articles

The Carolina Urologic Research Center expert discusses the benefits of oral relugolix for patients with prostate cancer.

Neal D. Shore, MD, FACS Discusses Impact, Treatment Implications of the Phase III HERO Trial

An analysis of the secondary endpoint of the phase III CONDOR study showed PSMA scans had a profound impact on patient care.

Michael J. Morris, MD on the Impact of PyL-PET/CT Scans on the Clinical Management of Patients With Prostate Cancer

Final data analysis of SPARTAN trial demonstrates large benefit in overall survival when compared with ADT plus placebo.

Apalutimide Plus ADT Improves Survival in Nonmetastatic Castration-Resistant Prostate Cancer

Baseline CTC counts were shown to be strong indicators for subsequent therapy response and 2-year progression-free survival.

Amir Goldkorn, MD Discusses Baseline CTC Count as a Prognostic Marker of PSA Response and Progression in mCSPC

The results suggested the potential for this agent to become a new standard for T-suppression in this patient population.

Phase III HERO Trial Finds Relugolix to be Superior to Leuprolide in Prostate Cancer 

The results, presented at the 2020 ASCO Virtual Scientific Program, found that in men with metastatic castration resistant prostate cancer who were previously treated with docetaxel, 177Lu-PSMA-617 (LuPSMA) was more active than cabazitaxel.

Phase II Trial Finds LuPSMA May be Effective for Men with mCRPC

The TAXOMET trial tested the addition of metformin to docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer.

ASCO Annual Meeting: Prostate Cancer | Conference